{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:21:26Z","timestamp":1793848886654,"version":"4.6.1"},"reference-count":141,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["42176098"],"award-info":[{"award-number":["42176098"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.heliyon.2024.e31105","type":"journal-article","created":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T02:59:55Z","timestamp":1715396395000},"page":"e31105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["A comprehensive review on ziconotide"],"prefix":"10.1016","volume":"10","author":[{"given":"Jinping","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usman Dawood","family":"Butt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1355-1261","authenticated-orcid":false,"given":"Min","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7638-2696","authenticated-orcid":false,"given":"Bin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e31105_bib1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.pain.2008.04.025","article-title":"The kyoto protocol of IASP basic pain terminology","volume":"137","author":"Loeser","year":"2008","journal-title":"Pain"},{"key":"10.1016\/j.heliyon.2024.e31105_bib2","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.2174\/1570159X19666210713121217","article-title":"Animal venom peptides cause antinociceptive effects by voltage-gated calcium channels activity blockage","volume":"20","author":"Trevisan","year":"2022","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.heliyon.2024.e31105_bib3","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/annonc\/mdp001","article-title":"Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes","volume":"20","author":"Breivik","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.heliyon.2024.e31105_bib4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JGO.2016.004663","article-title":"Assessment of adequacy of pain management and analgesic use in patients with advanced cancer using the brief pain inventory and pain management index calculation","volume":"3","author":"Singh","year":"2017","journal-title":"J Glob Oncol"},{"key":"10.1016\/j.heliyon.2024.e31105_bib5","first-page":"1","article-title":"Emotional and motivational pain processing: current state of knowledge and perspectives in translational research","volume":"2018","author":"Becker","year":"2018","journal-title":"Pain Res. Manag."},{"key":"10.1016\/j.heliyon.2024.e31105_bib6","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.neurom.2022.08.458","article-title":"Ziconotide for the management of cancer pain: a budget impact analysis","volume":"26","author":"Lambe","year":"2023","journal-title":"Neuromodulation: Technology at the Neural Interface"},{"key":"10.1016\/j.heliyon.2024.e31105_bib7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1152\/physrev.00023.2013","article-title":"Calcium-permeable ion channels in pain signaling","volume":"94","author":"Bourinet","year":"2014","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.heliyon.2024.e31105_bib8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0304-3959(99)00187-6","article-title":"The economic burden of back pain in the UK","volume":"84","author":"Maniadakis","year":"2000","journal-title":"Pain"},{"key":"10.1016\/j.heliyon.2024.e31105_bib9","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3399\/bjgp20X713549","article-title":"Drugs for chronic pain","volume":"70","author":"Shaheed","year":"2020","journal-title":"Br. J. Gen. Pract."},{"key":"10.1016\/j.heliyon.2024.e31105_bib10","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1172\/JCI43766","article-title":"Central modulation of pain","volume":"120","author":"Ossipov","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.heliyon.2024.e31105_bib11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.280.2.147","article-title":"Persistent pain and well-being: a world health organization study in primary care","volume":"280","author":"Gureje","year":"1998","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.heliyon.2024.e31105_bib12","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.2147\/JPR.S139715","article-title":"Adequacy of cancer-related pain management and predictors of undertreatment at referral to a pain clinic","volume":"10","author":"Reis-Pina","year":"2017","journal-title":"J. Pain Res."},{"key":"10.1016\/j.heliyon.2024.e31105_bib13","first-page":"15","article-title":"Update on prevalence of pain in patients with cancer 2022: a systematic literature review and meta-analysis","author":"Snijders","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.heliyon.2024.e31105_bib14","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1212\/01.wnl.0000282763.29778.59","article-title":"Neuropathic pain: redefinition and a grading system for clinical and research purposes","volume":"70","author":"Treede","year":"2008","journal-title":"NEUROLOGY"},{"key":"10.1016\/j.heliyon.2024.e31105_bib15","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0304-3959(94)90003-5","article-title":"Cognitive-behavioral classifications of chronic pain: replication and extension of empirically derived patient profiles","volume":"57","author":"Jamison","year":"1994","journal-title":"Pain"},{"key":"10.1016\/j.heliyon.2024.e31105_bib16","doi-asserted-by":"crossref","first-page":"406S","DOI":"10.1093\/ajh\/4.7.406S","article-title":"Pharmacology of calcium channels in cardiac muscle, vascular muscle, and neurons","volume":"4","author":"Bean","year":"1991","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.heliyon.2024.e31105_bib17","doi-asserted-by":"crossref","first-page":"6363","DOI":"10.1523\/JNEUROSCI.0307-07.2007","article-title":"Differential role of N-type calcium channel splice isoforms in pain","volume":"27","author":"Altier","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.heliyon.2024.e31105_bib18","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/nn.2643","article-title":"Opioid inhibition of N-type Ca2+ channels and spinal analgesia couple to alternative splicing","volume":"13","author":"Andrade","year":"2010","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.heliyon.2024.e31105_bib19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1006\/mcne.1994.1026","article-title":"Characterization of the binding of omega-conopeptides to different classes of non-L-type neuronal calcium channels","volume":"5","author":"Kristipati","year":"1994","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.heliyon.2024.e31105_bib20","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/316440a0","article-title":"Three types of neuronal calcium channel with different calcium agonist sensitivity","volume":"316","author":"Nowycky","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e31105_bib21","first-page":"79","article-title":"Regulation of presynaptic calcium channels by synaptic proteins","volume":"92","author":"Zamponi","year":"2003","journal-title":"J. Pharmacol. Sci. (Tokyo, Jpn.)"},{"key":"10.1016\/j.heliyon.2024.e31105_bib22","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1523\/JNEUROSCI.14-05-02800.1994","article-title":"Omega-conotoxin sensitivity and presynaptic inhibition of glutamatergic sensory neurotransmission in vitro","volume":"14","author":"Gruner","year":"1994","journal-title":"J. Neurosci."},{"key":"10.1016\/j.heliyon.2024.e31105_bib23","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.bmcl.2010.11.067","article-title":"A potent and selective indole N-type calcium channel (Ca(v)2.2) blocker for the treatment of pain","volume":"21","author":"Tyagarajan","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.heliyon.2024.e31105_bib24","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0003-9861(82)90351-4","article-title":"Isolation and structure of a peptide toxin from the marine snail Conus magus","volume":"218","author":"McIntosh","year":"1982","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.heliyon.2024.e31105_bib25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000438449","article-title":"Prey-capture strategies of fish-hunting cone snails: behavior, neurobiology and evolution","volume":"86","author":"Olivera","year":"2015","journal-title":"Brain Behav. Evol."},{"key":"10.1016\/j.heliyon.2024.e31105_bib26","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3390\/md21030154","article-title":"Bibliometric review of the literature on cone snail peptide toxins from 2000 to 2022","volume":"21","author":"Nguyen","year":"2023","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.heliyon.2024.e31105_bib27","first-page":"1633","article-title":"Venoms classification and therapeutic uses: a narrative review","volume":"27","author":"Morsy","year":"2023","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.heliyon.2024.e31105_bib28","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/S0041-0101(98)00158-5","article-title":"Pharmacotherapeutic potential of omega-conotoxin MVIIA (SNX-111), an N-type neuronal calcium channel blocker found in the venom of Conus magus","volume":"36","author":"Bowersox","year":"1998","journal-title":"Toxicon"},{"key":"10.1016\/j.heliyon.2024.e31105_bib29","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1517\/13543784.9.10.2403","article-title":"An evaluation of intrathecal ziconotide for the treatment of chronic pain","volume":"9","author":"Jain","year":"2000","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.heliyon.2024.e31105_bib30","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1517\/14656566.2013.784269","article-title":"Ziconotide: a clinical update and pharmacologic review","volume":"14","author":"Pope","year":"2013","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.heliyon.2024.e31105_bib31","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1592\/phco.2005.25.8.1084","article-title":"Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain","volume":"25","author":"Wermeling","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.heliyon.2024.e31105_bib32","article-title":"A chemoenzymatic approach to produce a cyclic analogue of the analgesic drug MVIIA (ziconotide)","volume":"62","author":"Zhou","year":"2023","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.heliyon.2024.e31105_bib33","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1006\/jmbi.1996.0576","article-title":"A consensus structure for omega-conotoxins with different selectivities for voltage-sensitive calcium channel subtypes: comparison of MVIIA, SVIB and SNX-202","volume":"263","author":"Nielsen","year":"1996","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.heliyon.2024.e31105_bib34","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0024-3205(03)00227-3","article-title":"Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling","volume":"73","author":"Rashid","year":"2003","journal-title":"Life Sci."},{"key":"10.1016\/j.heliyon.2024.e31105_bib35","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0014-5793(95)00819-U","article-title":"Solution structure of omega-conotoxin MVIIA using 2D NMR spectroscopy","volume":"370","author":"Basus","year":"1995","journal-title":"FEBS Lett."},{"key":"10.1016\/j.heliyon.2024.e31105_bib36","doi-asserted-by":"crossref","first-page":"8076","DOI":"10.1021\/bi00025a013","article-title":"Structure-activity analysis of a Conus peptide blocker of N-type neuronal calcium channels","volume":"34","author":"Nadasdi","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.heliyon.2024.e31105_bib37","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1161\/hq0202.104274","article-title":"Involvement of rho-kinase in agonists-induced contractions of arteriosclerotic human arteries","volume":"22","author":"Kandabashi","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.heliyon.2024.e31105_bib38","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41586-021-03699-6","article-title":"Structure of human Ca(v)2.2 channel blocked by the painkiller ziconotide","volume":"596","author":"Gao","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e31105_bib39","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/nedt.2007.3.1.69","article-title":"Ziconotide: a review of its pharmacology and use in the treatment of pain","volume":"3","author":"McGivern","year":"2007","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.heliyon.2024.e31105_bib40","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1093\/pm\/pnaa251","article-title":"Ziconotide for management of cancer pain refractory to pharmacotherapy: an update","volume":"21","author":"Banik","year":"2020","journal-title":"Pain Med."},{"key":"10.1016\/j.heliyon.2024.e31105_bib41","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/10915810701582970","article-title":"Nonclinical safety of ziconotide: an intrathecal analgesic of a new pharmaceutical class","volume":"26","author":"Skov","year":"2007","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.heliyon.2024.e31105_bib42","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1213\/ane.0b013e3181606fad","article-title":"Intrathecal ziconotide for severe chronic pain: safety and tolerability results of an open-label, long-term trial","volume":"106","author":"Wallace","year":"2008","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.heliyon.2024.e31105_bib43","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1517\/14656566.9.9.1575","article-title":"Ziconotide: an update and review","volume":"9","author":"Williams","year":"2008","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.heliyon.2024.e31105_bib44","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/10915810701582970","article-title":"Nonclinical safety of ziconotide: an intrathecal analgesic of a new pharmaceutical class","volume":"26","author":"Skov","year":"2007","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.heliyon.2024.e31105_bib45","doi-asserted-by":"crossref","first-page":"15728","DOI":"10.1074\/jbc.M100406200","article-title":"Residue Gly1326 of the N-type calcium channel alpha 1B subunit controls reversibility of omega-conotoxin GVIA and MVIIA block","volume":"276","author":"Feng","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.heliyon.2024.e31105_bib46","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.pmr.2022.01.004","volume":"33","author":"Ericson","year":"2022","journal-title":"Intrathecal Pumps, Physical Medicine and Rehabilitation Clinics of North America"},{"key":"10.1016\/j.heliyon.2024.e31105_bib47","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.nurt.2007.10.070","article-title":"Intrathecal pumps","volume":"5","author":"Belverud","year":"2008","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.heliyon.2024.e31105_bib48","doi-asserted-by":"crossref","first-page":"96","DOI":"10.12688\/f1000research.2-96.v1","article-title":"Intrathecal Drug Delivery (ITDD) systems for cancer pain","volume":"2","author":"Bhatia","year":"2013","journal-title":"F1000Res"},{"key":"10.1016\/j.heliyon.2024.e31105_bib49","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0025-6196(26)01499-0","article-title":"Continuous low-dose intrathecal morphine administration in the treatment of chronic pain of malignant origin","volume":"56","author":"Onofrio","year":"1981","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.heliyon.2024.e31105_bib50","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1213\/00000539-199108000-00019","article-title":"Spinal anesthesia using subcutaneously implanted pumps for intrathecal drug infusion","volume":"73","author":"Coombs","year":"1991","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.heliyon.2024.e31105_bib51","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/978-1-4939-9798-5_3","article-title":"Intrathecal drug delivery","volume":"2059","author":"De Andres","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.heliyon.2024.e31105_bib52","first-page":"615","article-title":"Current perspectives on intrathecal drug delivery","volume":"7","author":"Bottros","year":"2014","journal-title":"J. Pain Res."},{"key":"10.1016\/j.heliyon.2024.e31105_bib53","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1526-4637.2007.00356.x","article-title":"Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain","volume":"9","author":"Webster","year":"2008","journal-title":"Pain Med."},{"key":"10.1016\/j.heliyon.2024.e31105_bib54","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/pm\/pny132","article-title":"Intrathecal therapy for chronic pain: a review of morphine and ziconotide as firstline options","volume":"20","author":"Deer","year":"2019","journal-title":"Pain Med."},{"key":"10.1016\/j.heliyon.2024.e31105_bib55","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/14656566.2019.1707182","article-title":"How has ziconotide impacted non-cancer pain management?","volume":"21","author":"Deer","year":"2020","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.heliyon.2024.e31105_bib56","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1177\/0091270003253349","article-title":"Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients","volume":"43","author":"Wermeling","year":"2003","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e31105_bib57","first-page":"1569","article-title":"Ziconotide for treatment of severe chronic pain","volume":"375","author":"Schmidtko","year":"2010","journal-title":"The Lancet (British edition)"},{"key":"10.1016\/j.heliyon.2024.e31105_bib58","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1586\/14737175.6.10.1423","article-title":"Ziconotide: a new nonopioid intrathecal analgesic for the treatment of chronic pain","volume":"6","author":"Wallace","year":"2006","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.heliyon.2024.e31105_bib59","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1345\/aph.1G584","article-title":"Intrathecal ziconotide for refractory chronic pain","volume":"40","author":"Lynch","year":"2006","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.heliyon.2024.e31105_bib60","doi-asserted-by":"crossref","first-page":"478","DOI":"10.5414\/CPP44478","article-title":"Ziconotide--a novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain--a short review","volume":"44","author":"Klotz","year":"2006","journal-title":"Int. J. Clin. Pharm. Ther."},{"key":"10.1016\/j.heliyon.2024.e31105_bib61","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2174\/1570159X14666160210142056","article-title":"Ziconotide monotherapy: a systematic review of randomised controlled trials","volume":"15","author":"Brookes","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.heliyon.2024.e31105_bib62","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1525-1403.2012.00479.x","article-title":"Pharmacokinetic analysis of ziconotide (SNX-111), an intrathecal N-type calcium channel blocking analgesic, delivered by bolus and infusion in the dog","volume":"15","author":"Yaksh","year":"2012","journal-title":"Neuromodulation"},{"key":"10.1016\/j.heliyon.2024.e31105_bib63","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.bbi.2016.03.003","article-title":"Spinal activity of interleukin 6 mediates myelin basic protein-induced allodynia","volume":"56","author":"Ko","year":"2016","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.heliyon.2024.e31105_bib64","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/ner.12538","article-title":"The polyanalgesic consensus conference (PACC): recommendations on intrathecal drug infusion systems best practices and guidelines","volume":"20","author":"Deer","year":"2017","journal-title":"Neuromodulation"},{"key":"10.1016\/j.heliyon.2024.e31105_bib65","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.neurom.2022.02.230","article-title":"Dorsal vs ventral intrathecal catheter tip location and effect on dose escalation and opioid use in patients with cancer pain","volume":"26","author":"Brogan","year":"2022","journal-title":"Neuromodulation"},{"key":"10.1016\/j.heliyon.2024.e31105_bib66","first-page":"727","article-title":"Intrathecal therapy with ziconotide: clinical experience and considerations on its use","volume":"74","author":"Vitale","year":"2008","journal-title":"Minerva Anestesiol."},{"key":"10.1016\/j.heliyon.2024.e31105_bib67","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s10194-016-0708-8","article-title":"The status of diagnosis and treatment to intracranial hypotension, including SIH","volume":"18","author":"Lin","year":"2017","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.heliyon.2024.e31105_bib68","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/j.1526-4610.2010.01699.x","article-title":"Post-dural puncture headache: part I diagnosis, epidemiology, etiology, and pathophysiology","volume":"50","author":"Bezov","year":"2010","journal-title":"Headache"},{"key":"10.1016\/j.heliyon.2024.e31105_bib69","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1259\/bjr\/66206791","article-title":"Cerebrospinal fluid flow imaging by using phase-contrast MR technique","volume":"84","author":"Battal","year":"2011","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.heliyon.2024.e31105_bib70","article-title":"Intrathecal administration of ziconotide as a potential treatment for chronic migraines","volume":"14","author":"Holden","year":"2022","journal-title":"Cureus J. Med. Sci."},{"key":"10.1016\/j.heliyon.2024.e31105_bib71","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.2016.1464","article-title":"CDC guideline for prescribing opioids for chronic pain--United States, 2016","volume":"315","author":"Dowell","year":"2016","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.heliyon.2024.e31105_bib72","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.2174\/0929867043363884","article-title":"Ziconotide: neuronal calcium channel blocker for treating severe chronic pain","volume":"11","author":"Miljanich","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e31105_bib73","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.291.1.63","article-title":"Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial","volume":"291","author":"Staats","year":"2004","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.heliyon.2024.e31105_bib74","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4103\/sni.sni_80_17","article-title":"Intrathecal catheter-associated inflammatory mass in a neurofibromatosis type-1 patient receiving fentanyl and bupivacaine","volume":"8","author":"Southwell","year":"2017","journal-title":"Surg. Neurol. Int."},{"key":"10.1016\/j.heliyon.2024.e31105_bib75","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1080\/17512433.2019.1659724","article-title":"Choice of intrathecal drug in the treatment of neuropathic pain - new research and opinion","volume":"12","author":"Deer","year":"2019","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e31105_bib76","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1592\/phco.2005.25.8.1084","article-title":"Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain","volume":"25","author":"Wermeling","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.heliyon.2024.e31105_bib77","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.nec.2022.02.007","article-title":"The role of intrathecal pumps in nonmalignant pain","volume":"33","author":"Ginalis","year":"2022","journal-title":"Neurosurgery Clinics of America"},{"key":"10.1016\/j.heliyon.2024.e31105_bib78","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/ner.12543","article-title":"The polyanalgesic consensus conference (PACC): recommendations for trialing of intrathecal drug delivery infusion therapy","volume":"20","author":"Deer","year":"2017","journal-title":"Neuromodulation: Technology at the Neural Interface"},{"key":"10.1016\/j.heliyon.2024.e31105_bib79","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/ner.12579","article-title":"The polyanalgesic consensus conference (PACC): recommendations for intrathecal drug delivery: guidance for improving safety and mitigating risks","volume":"20","author":"Deer","year":"2017","journal-title":"Neuromodulation: Technology at the Neural Interface"},{"key":"10.1016\/j.heliyon.2024.e31105_bib91","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0304-3959(99)00255-9","article-title":"Ziconotide for the treatment of severe spasticity after spinal cord injury","volume":"85","author":"Ridgeway","year":"2000","journal-title":"Pain"},{"key":"10.1016\/j.heliyon.2024.e31105_bib81","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jpainsymman.2006.08.002","article-title":"An effective treatment of severe complex regional pain syndrome type 1 in a child using high doses of intrathecal ziconotide","volume":"32","author":"Stanton-Hicks","year":"2006","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.heliyon.2024.e31105_bib80","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bpa.2023.02.003","article-title":"Intrathecal drug delivery in the management of chronic pain","volume":"37","author":"Van Zundert","year":"2023","journal-title":"Best Pract. Res. Clin. Anaesthesiol."},{"key":"10.1016\/j.heliyon.2024.e31105_bib114","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ijoa.2011.06.009","article-title":"Ultrasound guided epidural analgesia for labor in a patient with an intrathecal baclofen pump","volume":"20","author":"Badve","year":"2011","journal-title":"International Journal of Obstetric Anestjesia"},{"key":"10.1016\/j.heliyon.2024.e31105_bib122","first-page":"2565","volume":"10","author":"Adler","year":"2017","journal-title":"Intrathecal pain management: a team-based approach"},{"key":"10.1016\/j.heliyon.2024.e31105_bib82","year":"2006","journal-title":"Ziconotide"},{"key":"10.1016\/j.heliyon.2024.e31105_bib83","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1602\/neurorx.2.4.662","article-title":"Targeting chronic and neuropathic pain: the N-type calcium channel comes of age","volume":"2","author":"Snutch","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.heliyon.2024.e31105_bib84","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s40263-013-0107-5","article-title":"Intrathecal ziconotide: a review of its use in patients with chronic pain refractory to other systemic or intrathecal analgesics","volume":"27","author":"Sanford","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.heliyon.2024.e31105_bib85","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1525-1403.2006.00055.x","article-title":"Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial","volume":"9","author":"Wallace","year":"2006","journal-title":"Neuromodulation"},{"key":"10.1016\/j.heliyon.2024.e31105_bib86","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jpainsymman.2005.10.003","article-title":"A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain","volume":"31","author":"Rauck","year":"2006","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.heliyon.2024.e31105_bib87","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1525-1403.2012.00476.x","article-title":"Polyanalgesic Consensus Conference 2012: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel","volume":"15","author":"Deer","year":"2012","journal-title":"Neuromodulation"},{"key":"10.1016\/j.heliyon.2024.e31105_bib88","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1533-2500.2009.00308.x","article-title":"Intrathecal therapy: what has changed with the introduction of ziconotide","volume":"9","author":"Kress","year":"2009","journal-title":"Pain Pract."},{"key":"10.1016\/j.heliyon.2024.e31105_bib89","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2147\/JPR.S129661","article-title":"Complex management of a patient with refractory primary erythromelalgia lacking a SCN9A mutation","volume":"10","author":"Low","year":"2017","journal-title":"J. Pain Res."},{"key":"10.1016\/j.heliyon.2024.e31105_bib90","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1213\/XAA.0000000000000978","article-title":"Low-dose intrathecal ziconotide for spasticity from primary lateral sclerosis: a case report","volume":"13","author":"Zhu","year":"2019","journal-title":"A & A Practice"},{"key":"10.1016\/j.heliyon.2024.e31105_bib92","first-page":"263","article-title":"Does pain relief influence recovery of consciousness? A case report of a patient treated with ziconotide","volume":"52","author":"Lanzillo","year":"2016","journal-title":"Eur. J. Phys. Rehabil. Med."},{"key":"10.1016\/j.heliyon.2024.e31105_bib93","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/j.wneu.2020.10.079","article-title":"Effect of first-line ziconotide intrathecal drug therapy for neuropathic pain on disability, emotional well-being, and pain catastrophizing","volume":"145","author":"Shao","year":"2021","journal-title":"World Neurosurgery"},{"key":"10.1016\/j.heliyon.2024.e31105_bib94","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1526-4637.2007.00355.x","article-title":"Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain","volume":"9","author":"Wallace","year":"2008","journal-title":"Pain Med."},{"key":"10.1016\/j.heliyon.2024.e31105_bib95","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0304-3959(99)00214-6","article-title":"Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats","volume":"84","author":"Wang","year":"2000","journal-title":"Pain"},{"key":"10.1016\/j.heliyon.2024.e31105_bib96","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-226793","article-title":"Pancoast's syndrome caused by lymph node metastasis from breast cancer","volume":"11","author":"Di Stefano","year":"2018","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.heliyon.2024.e31105_bib97","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40122-020-00169-1","article-title":"Triple intrathecal combination therapy for end-stage cancer-related refractory pain: a prospective observational study with two-month follow-up","volume":"9","author":"Puntillo","year":"2020","journal-title":"Pain and Therapy"},{"key":"10.1016\/j.heliyon.2024.e31105_bib98","first-page":"274","article-title":"Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain","volume":"25","author":"Atanassoff","year":"2000","journal-title":"Reg. Anesth. Pain Med."},{"key":"10.1016\/j.heliyon.2024.e31105_bib99","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1055\/s-0029-1202359","article-title":"Formation of two consecutive intrathecal catheter tip granulomas within nine months","volume":"71","author":"Hoederath","year":"2010","journal-title":"Cent. Eur. Neurosurg."},{"key":"10.1016\/j.heliyon.2024.e31105_bib100","first-page":"457","article-title":"Voltage-gated calcium channels as targets for the treatment of chronic pain","volume":"3","author":"McGivern","year":"2004","journal-title":"Curr. Drug Targets: CNS Neurol. Disord."},{"key":"10.1016\/j.heliyon.2024.e31105_bib104","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2147\/TCRM.S4438","article-title":"Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain","volume":"5","author":"Smith","year":"2009","journal-title":"Therapeut. Clin. Risk Manag."},{"key":"10.1016\/j.heliyon.2024.e31105_bib133","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3390\/md21040229","article-title":"Self-assembly nanostructure of myristoylated \u03c9-conotoxin MVIIA increases the duration of efficacy and reduces side effects","volume":"21","author":"Ding","year":"2023","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.heliyon.2024.e31105_bib101","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1124\/mi.7.5.7","article-title":"Diversity of the neurotoxic Conus peptides: a model for concerted pharmacological discovery","volume":"7","author":"Olivera","year":"2007","journal-title":"Mol. Interv."},{"key":"10.1016\/j.heliyon.2024.e31105_bib102","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0196-9781(00)00175-3","article-title":"Bioavailability of Ziconotide in brain: influx from blood, stability, and diffusion","volume":"21","author":"Newcomb","year":"2000","journal-title":"Peptides"},{"key":"10.1016\/j.heliyon.2024.e31105_bib117","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/papr.12111","article-title":"Intrathecal drug administration in chronic pain syndromes","volume":"14","author":"Ver Donck","year":"2013","journal-title":"Pain Pract."},{"key":"10.1016\/j.heliyon.2024.e31105_bib118","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2147\/JPR.S46929","article-title":"Programmable intrathecal pumps for the management of chronic pain: recommendations for improved efficiency","volume":"7","author":"Wilkes","year":"2014","journal-title":"J. Pain Res."},{"key":"10.1016\/j.heliyon.2024.e31105_bib119","first-page":"347","article-title":"Chemical stability of morphine, ropivacaine, and ziconotide in combination for intrathecal analgesia","volume":"21","author":"Robert","year":"2017","journal-title":"Int. J. Pharm. Compd."},{"key":"10.1016\/j.heliyon.2024.e31105_bib120","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.3171\/foc.2006.21.2.6","article-title":"Intrathecal baclofen in the treatment of adult spasticity","volume":"21","author":"Hsieh","year":"2006","journal-title":"Neurosurg. Focus"},{"key":"10.1016\/j.heliyon.2024.e31105_bib103","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/00002508-200109000-00004","article-title":"Evaluation of patients for implantable pain modalities: medical and behavioral assessment","volume":"17","author":"Prager","year":"2001","journal-title":"Clin. J. Pain"},{"key":"10.1016\/j.heliyon.2024.e31105_bib105","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/104990910502200510","article-title":"Ziconotide: can we use it in palliative care?","volume":"22","author":"Prommer","year":"2005","journal-title":"Am. J. Hosp. Palliat. Med."},{"key":"10.1016\/j.heliyon.2024.e31105_bib106","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0006-8993(00)02289-7","article-title":"Immunohistochemical study on the distribution of the voltage-gated calcium channel alpha(1B) subunit in the mature rat brain","volume":"866","author":"Chung","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.heliyon.2024.e31105_bib107","first-page":"19","article-title":"Using ziconotide for intrathecal infusions","volume":"38","author":"Mitchell","year":"2008","journal-title":"Nurs. Res. Rev."},{"key":"10.1016\/j.heliyon.2024.e31105_bib108","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jpainsymman.2008.02.016","article-title":"Long-term intrathecal ziconotide for chronic pain: an open-label study","volume":"37","author":"Webster","year":"2009","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.heliyon.2024.e31105_bib109","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.neuron.2008.03.002","article-title":"D1 receptors physically interact with N-type calcium channels to regulate channel distribution and dendritic calcium entry","volume":"58","author":"Kisilevsky","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.heliyon.2024.e31105_bib110","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00482-021-00531-y","article-title":"Was wurde eigentlich aus Prialt","volume":"35","author":"L\u00f6schner","year":"2021","journal-title":"Schmerz"},{"key":"10.1016\/j.heliyon.2024.e31105_bib111","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.neuropharm.2015.08.047","article-title":"Molecular basis of toxicity of N-type calcium channel inhibitor MVIIA","volume":"101","author":"Wang","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.heliyon.2024.e31105_bib112","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.taap.2017.10.017","article-title":"Effects of opioid and nonopioid analgesics on canine wheal formation and cultured human mast cell degranulation","volume":"338","author":"Schmidt-Rondon","year":"2018","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e31105_bib113","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1213\/ANE.0000000000004639","article-title":"The rate of infectious complications after intrathecal drug delivery system implant for cancer-related pain is low despite frequent concurrent anticancer treatment or leukopenia","volume":"131","author":"Sindt","year":"2020","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.heliyon.2024.e31105_bib115","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/j.1526-4637.2010.00876.x","article-title":"Intrathecal opioid therapy for chronic nonmalignant pain: a retrospective cohort study with 3-year follow-up","volume":"11","author":"Atli","year":"2010","journal-title":"Pain Med."},{"key":"10.1016\/j.heliyon.2024.e31105_bib116","first-page":"e46","article-title":"Transverse myelopathy following intrathecal administration of chemotherapy","volume":"48","author":"Teh","year":"2007","journal-title":"Singapore Medical Journal"},{"key":"10.1016\/j.heliyon.2024.e31105_bib121","first-page":"115","article-title":"Magnetic fields and intrathecal pump malfunction","volume":"34","author":"Huh","year":"2016","journal-title":"AJEM (Am. J. Emerg. Med.)"},{"key":"10.1016\/j.heliyon.2024.e31105_bib123","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/00325481.2018.1448207","article-title":"Role of primary care physicians in intrathecal pain management: a narrative review of the literature","volume":"130","author":"McDowell","year":"2018","journal-title":"PGM (Postgrad. Med.)"},{"key":"10.1016\/j.heliyon.2024.e31105_bib124","first-page":"118","article-title":"Ziconotide: indications, adverse effects, and limitations in managing refractory chronic pain","volume":"24","author":"Nair","year":"2018","journal-title":"Indian J. Palliat. Care"},{"key":"10.1016\/j.heliyon.2024.e31105_bib125","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/ner.12880","article-title":"Perioperative and periprocedural care of patients with intrathecal pump therapy","volume":"22","author":"Nadherny","year":"2019","journal-title":"Neuromodulation"},{"key":"10.1016\/j.heliyon.2024.e31105_bib126","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/rapm-2022-103770","article-title":"Controversies in intrathecal drug delivery for cancer pain","volume":"48","author":"Brogan","year":"2023","journal-title":"Reg. Anesth. Pain Med."},{"key":"10.1016\/j.heliyon.2024.e31105_bib127","doi-asserted-by":"crossref","DOI":"10.1038\/srep12497","article-title":"Tailored delivery of analgesic ziconotide across a blood brain barrier model using viral nanocontainers","volume":"5","author":"Anand","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2024.e31105_bib128","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/cbdd.12055","article-title":"The future of peptide-based drugs","volume":"81","author":"Craik","year":"2013","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.heliyon.2024.e31105_bib129","doi-asserted-by":"crossref","first-page":"9971","DOI":"10.1021\/acs.chemrev.8b00657","article-title":"Ligation technologies for the Synthesis of cyclic peptides","volume":"119","author":"Chow","year":"2019","journal-title":"Chem. Rev."},{"key":"10.1016\/j.heliyon.2024.e31105_bib130","doi-asserted-by":"crossref","first-page":"19073","DOI":"10.1002\/anie.201911900","article-title":"CyClick chemistry for the Synthesis of cyclic peptides","volume":"58","author":"Adebomi","year":"2019","journal-title":"Angewandte Chemie-international Edition"},{"key":"10.1016\/j.heliyon.2024.e31105_bib131","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1126\/science.7973629","article-title":"Synthesis of proteins by native chemical ligation","volume":"266","author":"Dawson","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.heliyon.2024.e31105_bib132","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jconrel.2023.03.007","article-title":"Microneedle-mediated delivery of Ziconotide-loaded liposomes fused with exosomes for analgesia","volume":"356","author":"Song","year":"2023","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.heliyon.2024.e31105_bib134","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3390\/md20080531","article-title":"Conotoxin patenting trends in academia and industry","volume":"20","author":"Sanchez-Campos","year":"2022","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.heliyon.2024.e31105_bib135","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.brainresrev.2008.12.021","article-title":"Role of voltage-gated calcium channels in ascending pain pathways","volume":"60","author":"Zamponi","year":"2009","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.heliyon.2024.e31105_bib136","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4103\/0975-7406.171700","article-title":"Exploring the ocean for new drug developments: marine pharmacology","volume":"8","author":"Malve","year":"2016","journal-title":"J. Pharm. BioAllied Sci."},{"key":"10.1016\/j.heliyon.2024.e31105_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.foodres.2020.109637","article-title":"High-value compounds from the molluscs of marine and estuarine ecosystems as prospective functional food ingredients: an overview","volume":"137","author":"Chakraborty","year":"2020","journal-title":"Food Res. Int."},{"key":"10.1016\/j.heliyon.2024.e31105_bib138","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.bcp.2005.04.035","article-title":"Use-dependent blockade of Cav2.2 voltage-gated calcium channels for neuropathic pain","volume":"70","author":"Winquist","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e31105_bib139","doi-asserted-by":"crossref","first-page":"20171","DOI":"10.1074\/jbc.M300581200","article-title":"Determinants of inhibition of transiently expressed voltage-gated calcium channels by omega-conotoxins GVIA and MVIIA","volume":"278","author":"Feng","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.heliyon.2024.e31105_bib140","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41422-022-00616-y","article-title":"Inhibiting Hv1 channel in peripheral sensory neurons attenuates chronic inflammatory pain and opioid side effects","volume":"32","author":"Zhang","year":"2022","journal-title":"Cell Res."},{"key":"10.1016\/j.heliyon.2024.e31105_bib141","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.neurom.2021.10.002","article-title":"Physicochemical stability study of the morphine-ropivacaine-ziconotide association in implantable pumps for intrathecal administration","volume":"26","author":"Robert","year":"2022","journal-title":"Neuromodulation: Technology at the Neural Interface"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024071366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024071366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:53:13Z","timestamp":1790239993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024071366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":141,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2405844024071366"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e31105","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comprehensive review on ziconotide","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e31105","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e31105"}}